Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 24, No 28 (October 1), 2006: pp. 4581-4586
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.05.9592

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Tol-Geerdink, J. J.
Right arrow Articles by Leer, J.-W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Tol-Geerdink, J. J.
Right arrow Articles by Leer, J.-W.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Do Patients With Localized Prostate Cancer Treatment Really Want More Aggressive Treatment?

Julia J. van Tol-Geerdink, Peep F.M. Stalmeier, Emile N.J.T. van Lin, Eric C. Schimmel, Henk Huizenga, Wim A.J. van Daal, Jan-Willem Leer

From the Departments of Radiation Oncology and Medical Technology Assessment, Radboud University Nijmegen Medical Center, Nijmegen; and the Arnhems Radiotherapeutic Institute, Arnhem, the Netherlands

Address reprint requests to Julia J. van Tol-Geerdink, PhD, Department of Radiation Oncology (874), Radboud University Nijmegen Medical Center, PO Box 9101, 6500 HB Nijmegen, the Netherlands; e-mail: J.vanTol{at}rther.umcn.nl

PURPOSE: Examine whether patients with prostate cancer choose the more aggressive of two radiotherapeutic options, whether this choice is reasoned, and what the determinants of the choice are.

PATIENTS AND METHODS: One hundred fifty patients with primary prostate cancer (T1-3N0M0) were informed by means of a decision aid of two treatment options: radiotherapy with 70 Gy versus 74 Gy. The latter treatment is associated with more cure and more toxicity. The patients were asked whether they wanted to choose, and if so which treatment they preferred. They also assigned importance weights to the probability of various outcomes, such as survival, cure and adverse effects. Patients who wanted to choose their own treatment (n = 119) are described here.

RESULTS: The majority of these patients (75%) chose the lower radiation dose. Their choice was highly consistent (P ≤ .001), with the importance weights assigned to the probability of survival, cure (odds ratio [OR] = 6.7 and 6.9) and late GI and genitourinary adverse effects (OR = 0.1 and 0.2). The lower dose was chosen more often by the older patients, low-risk patients, patients without hormone treatment, and patients with a low anxiety or depression score.

CONCLUSION: Most patients with localized prostate cancer prefer the lower radiation dose. Our findings indicate that many patients attach more weight to specific quality-of-life aspects (eg, GI toxicity) than to improving survival. Treatment preferences of patients with localized prostate cancer can and should be involved in radiotherapy decision making.

Supported in part by Grants No. KUN 2001-2379 and 2005-3457 from the Dutch Cancer Society, Amsterdam, the Netherlands.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Jpn J Clin OncolHome page
N. Soga, K. Arima, and Y. Sugimura
Undetectable Level of Prostate Specific Antigen (PSA) Nadir Predicts PSA Biochemical Failure in Local Prostate Cancer with Delayed-combined Androgen Blockade
Jpn. J. Clin. Oncol., September 1, 2008; 38(9): 617 - 622.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. F.M. Stalmeier, J. J. van Tol-Geerdink, E. N.J.Th. van Lin, E. Schimmel, H. Huizenga, W. A.J. van Daal, and J.-W. Leer
Doctors' and Patients' Preferences for Participation and Treatment in Curative Prostate Cancer Radiotherapy
J. Clin. Oncol., July 20, 2007; 25(21): 3096 - 3100.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. A. Audisio, A. P. Zbar, and M. T. Jaklitsch
Surgical Management of Oncogeriatric Patients
J. Clin. Oncol., May 10, 2007; 25(14): 1924 - 1929.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online